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Abstract
In making an experience-based case for research advocacy in Africa and suggesting a framework for building it,
this paper covers factors such as basic tenets of patient advocacy, key components and urgent needs in building
strong research advocacy, concepts and approaches from which guidance might be taken, and the feasibility of its
development and growth throughout the continent. Research advocacy is defined as the meaningful engagement
of patient advocates and their representatives in the research system.
As the clinical research system in Africa is developing and gaining strength, this is an opportune time for research
advocacy to form and take root as an embedded component in the research structures on the continent. That is,
the current state of development of the research system and the simultaneous interest in and rise of patient
advocacy bode well for the likelihood of developing robust research advocacy, suggesting its feasibility. Even so,
several developments are urgently needed to build, shore up, and sustain a framework receptive to maximizing
the influence of an active network of patient advocates—many training in the subspecialty of research advocacy—
and a research structure that supports and embeds advocate engagement.
Introduction
In providing a case and framework for research advo-
cacy in Africa, this paper draws on the experience of
and infrastructure for research advocacy in the United
States of America (America), where it is an increasingly
present and influential component of the research land-
scape, and on lessons learned and observations made
over a 16-year period of active advocacy. Conclusions
are also drawn from engagement with an incredible
array of patients, survivors, caregivers, and others
involved in advocacy and in the research system. (See
Additional file 1, “A tribute to patients and survivors.”)
The modes of research advocacy throughout Africa
will differ from their American counterparts. They will
be aligned with country and regional norms, cultures,
religions, languages, and support. However, they can be
informed by the significance and uniqueness of contri-
butions of those who provide patient perspectives in
American cancer and research communities. Over nearly
three decades, at least since the founding in 1986 of the
cancer survivor-led National Coalition for Cancer Survi-
vorship [1], the impact of patient advocacy has grown
significantly. The essential framework in Africa—the
structure on which advocacy will stand—can be built on
principles that contribute to the success and influence
of patient and research advocacy in America.
Although patient advocacy is not a new concept in
Africa, it is a largely nascent one, with groups like the
Breast Cancer Association of Nigeria, Tanzania 50 Plus
Campaign (prostate cancer focused), and People Living
with Cancer (an umbrella organization focused on
South Africans living with cancer) dotting the health
landscape. Such groups and the growing continental
research capacity are bolstered through the work of
organizations like the African Organisation for Research
and Training in Cancer (AORTIC). Formed in 1983,
AORTIC’s key objectives are “to further the research
relating to cancers prevalent in Africa, support the man-
agement of training programs in oncology for health
care workers, deal with the challenges of creating cancer
control and prevention programs and raise publicCorrespondence: Nekima@aol.com
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awareness of cancer in Africa” [2]. Advocacy can also be
strengthened by looking to the considerable American
experience with and literature on patient advocacy, cul-
tural competence in research, and community-based
participatory research (CBPR).
The 2006 World Cancer Declaration recognized the
following: “By 2020, more than 16 million new cancer
cases and 10 million cancer deaths are expected
annually. Seventy percent of these deaths will likely
occur in developing countries that are unprepared to
address their growing cancer burden” [3]. These projec-
tions highlight the urgency for improved cancer control,
management, and care and for “collective action.”
Research advocates and other advocates can prove
instrumental in denying these projections a more solid
foothold.
Discussion
Basic tenets of research advocacy: making the case for it
Patient advocacy includes many subspecialties, a fairly
new but influential one being research advocacy. It is
useful to have a shared definition of a patient advocate
to discuss the value of patient and research advocacy.
The America National Cancer Institute (NCI) defines a
patient advocate as “A person who helps a patient work
with others who have an effect on the patient’s health,
including doctors, insurance companies, employers, case
managers, and lawyers.…Cancer advocacy groups try to
raise public awareness about important cancer issues,
such as the need for cancer support services, education,
and research. Such groups work to bring about change
that will help cancer patients and their families” [4].
Incorporated in the litany of services and engagement is
research advocacy, the meaningful engagement of
patient advocates and their representatives in the
research system, which is integral to changes in health
care research and service delivery.
The case for research advocacy in Africa is straightfor-
ward. There is an urgent need for all stakeholders to
converge, there is an opportunity for mutual benefit and
growth as the research system takes form and begins to
mature, and there are examples of advocacy-at-work
from which Africa can learn and model. As in the
American model, research advocacy will strengthen the
research process, change the way researchers see
patients and consider patient needs, and keep patients
at the center of research thinking and conduct. Research
and other patient advocates will:
• Put faces on the disease. Many researchers will have
encountered only the most ill patients at their very
worst.
• Give voice to all patients and survivors. Patient
voices are unique, experience-based, and indispensable,
and patients will need to have the courage to become
public about issues considered private and often
stigmatic.
• Ask questions specific to the lived experience of
cancer.
• Create a sense of urgency, by their very presence.
• Form mutually respectful and beneficial partnerships
and relationships with researchers. This is a significant
challenge, perhaps even a barrier, in a research system
that within some cultures has strict lines of separation
along lines of authority, responsibility, and class.
• Provide hope for patients, as patients need the
example of survival and peer support.
All of these will result in the conduct of research
more focused on issues important to patients, more
patient-friendly, and more likely to accrue, increasing
the prospect of ultimate benefit to patients.
A framework, not the framework
Given the case for research advocacy and the unusual
opportunity for it to develop in concert with the research
system on the continent, a possible framework, as
opposed to the only workable structure, is suggested.
This structure aligns with basic components of research
advocacy as it is practiced in America. Groups and indivi-
duals should feel free to borrow liberally from whatever
will work in country-, culture-, and population-specific
settings. It is not necessary to reinvent the wheel, but the
wheel must be usable on African roads and byways.
Embedded in the wheel of American patient and research
advocacy are concepts and models such as community-
based participatory research (CBPR) and “cultural com-
petence” in research. These concepts largely address
often significant concerns related to culture-, language-,
and population-specific differences.
The proposed framework is based on a partnership
between advocates and researchers, a natural alliance of
individuals with like goals and differing but complemen-
tary experience and skill sets. This alliance must be nur-
tured in Africa just as it continues to be nurtured and to
mature in America through training, ongoing engagement,
and growing mutual respect. CBPR, which is defined as “a
collaborative approach to research that equitably involves
all partners in the research process and recognizes the
unique strengths that each brings” [5], asserts the impor-
tance of full community participation in all elements of
the research process. In fact, the research topic must be
one of importance to the community being researched,
and the research findings must be reported to the commu-
nity. There are numerous examples of CBPR’s adaption
and success in America from which African countries can
draw. One example is the Deep South Network for Cancer
Control, a Cancer Network Program funded by the NCI
Center to Reduce Cancer Health Disparities and dedicated
to building on “established community and institutional
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capacity in order to eliminate cancer health disparities by
conducting community-based participatory education,
training and research” [6].
Research advocacy should be seen as critical for the
most patient-cantered, accruable research, as modelled
in CBPR. It is not, however, easy or for the faint of
heart or for the easily discouraged, a short-term project,
or free of costs. For example, it requires significant
funding, time, and effort. It also requires: (i) dedicated
advocates; (ii) a supportive advocacy network and
research system; (iii) an evolving state of mutual respect
and acceptance between advocates and researchers; (iv)
ongoing training and preparation for advocates and
researchers; and (v) private and public sector investment
and support. To promote the growth and influence of a
viable and active patient advocate network, the advocacy
framework must be country-specific and African-led,
with support from countries and regions with more
longstanding and robust networks.
Becoming an advocate
To provide ongoing research advocacy coverage, a pipe-
line of willing and able volunteers must emerge. This
pipeline of advocates can come from any walk of life,
with many research advocates beginning their efforts in
the subspecialties of support, community outreach, edu-
cation, political, and fundraising. Whatever their route
of entry, they are everyday citizens, including:
• Patients, survivors, family members, and caregivers.
• Curious, willing learners with or without a science
or medical background.
• Clear communicators and listeners with the ability
to read, write, and/or speak in the language of the popu-
lations represented or served.
• Members of health advocacy groups or other activist
efforts.
• Scientists and clinicians personally affected by
cancer.
• Other interested individuals with the time, lifestyle
ability, and commitment to ongoing training and contin-
uous education in the name of health care access,
patient benefit, needed change, and the common good.
This volunteer army of advocates can train and prepare
for research advocacy through numerous mechanisms.
Many are drawn to advocacy through personal or family
experience with cancer. They must however be motivated
to become fully participatory through several initiatives,
including: (i) individual study; (ii) advocacy group inter-
action and training; (iii) local, national, and international
programs focused on research training and networking;
(iv) attendance and participation at scientific meetings;
and (v) online resources if available. This list is not com-
prehensive, and individuals and groups can explore addi-
tional opportunities for research advocacy training. For
example, the Scientist-Survivor Program held at the
American Association for Cancer Research Annual meet-
ing is designed to build partnerships between scientists
and patients/survivors. It “exposes advocates to special
lay-language lectures, small group discussions and other
interactions that provide a solid background in cancer
research” [7]. The program offers an excellent training
opportunity, and advocates from all over the world parti-
cipate and network through the program.
Once trained, research advocates will grow in profi-
ciency and influence, providing patient perspectives and
keeping the focus firmly on patients. They can serve on
ethics committees, concept and protocol review panels,
research teams, grant funding panels, and other
research-focused groups. While their opportunities and
responsibilities may vary across the continent, within
countries, regions, and ethnic groups, research advocates
are important in the research process. Thus, they should
be willing to share their stories (primarily focusing on
the collective experience of patients and survivors), be
persistent but not longwinded or self-important in pro-
viding the patient point-of-view, demonstrate deep con-
cern and passion without conveying displaced anger and
resentment, and build relationships rather than mark
territory. They must stay focused on optimal patient
benefit and outcomes.
In focusing on patient benefit and outcomes, research
advocates concentrate on specific lines of inquiry and
often frame their comments and concerns as questions.
For example, they might ask:
• What can this research mean in terms of care, qual-
ity of life, and/or survival? Could the results change
practice or add treatment options?
• Does the trial include provisions to overcome possi-
ble barriers to patient participation such as distance
from the trial site, frequency of visits, incidental costs,
and language and culture-related issues?
• How tolerable are the side effects of the experimen-
tal drugs and/or procedures?
• Outside of the clinic or hospital, will the drug be
easy or practicable to take or administer?
• Will trial participants be able to work and/or take
care of home responsibilities and remain on the trial?
• Who will supply the experimental drugs? Will there
be a cost to trial participants?
• Who and what (groups, documents, and procedures)
will protect the interests and safety of trial participants?
Do you know who from the family or cultural group must
be present to make the decision about trial participation?
No one is better positioned to ask such questions or
has more at stake than patients and their advocates. Of
course, the actual questions asked and areas of focus
will be specific to local and population-specific concerns
and realities.
Scroggins Infectious Agents and Cancer 2013, 8(Suppl 1):S4
http://www.infectagentscancer.com/content/8/S1/S4
Page 3 of 6
The feasibility of research advocacy in Africa
The formation and first-year efforts of the African Can-
cer Advocates Consortium (ACAC) answer the question
of whether a viable African advocacy network is possi-
ble. It was formed, with 51 charter members, after the
“International Workshop on Cancer Advocacy for
African Countries” conducted during the 2011 AORTIC
Conference. In its first year, ACAC members have
remained engaged working on several initiatives. For
example, ACAC members were instrumental in provid-
ing case studies for the “Cancer Advocacy Training
Toolkit for Africa” published by AORTIC, the African
Oxford Cancer Foundation (AfrOx), the European
Society for Medical Oncology, and the Union for Inter-
national Cancer Control [8]. In addition, the ACAC lea-
dership proactively alerts African advocates about
advocacy education and training opportunities. ACAC is
the beginning of a robust network, with regional and
subspecialty representation (including research advo-
cacy). In a message to “Toolkit” users, David Kerr, foun-
der and trustee at AfrOx, noted, “One of the most
important ways we feel we can help to reduce the bur-
den of cancer in Africa is to work with African cancer
advocacy organizations to help educate and advocate
about cancer in their countries” [9].
Research advocacy is both feasible and doable. Active
existing advocacy groups, AORTIC support and work-
shops that provide training across advocacy subspecialties,
the regionally and subspecialty diverse ACAC model, and
the “Toolkit” serve as early evidence.
Urgent needs for forward movement
Among the most urgent needs in developing sustainable
and robust research advocacy in Africa are:
1. Public awareness efforts that put cancer on the
priority list of health issues in Africa.
2. A research structure that supports and embeds
research advocacy in its structure as a core value-added
component.
3. Active recruitment and development of a core and
pipeline of interested patients and other activists.
4. Ongoing training programs built, in part, through
collaboration and shared cornerstones among advocacy
groups across the continent and from other regions of
the world.
5. Global partnerships among advocates, researchers
and clinicians.
The power of collective action and networking: advocacy
experience
In 2005, while traveling in Kenya, the author and her
daughter Nneka spent time in an HIV/AIDS Collective in
a rural village (Figure 1). The vast majority of its
residents are HIV-positive women and young children,
with most of the husbands, fathers, and other adult males
having died from AIDS or AIDS-related complications.
To support the village, the surviving women sell lovely
baskets they weave. In an environment perhaps hostile
and unwelcoming, these courageous women also develop
and present plays to educate others about HIV/AIDS and
their experiences living with the infection or the disease.
This lovely ensemble gave a special performance for the
four purposeful travellers who made up our party,
demonstrated the use of PUR (a tablet used to purify
water from a pond they share with animals as a common
drinking source), cooked a simple but filling meal (with-
out request, providing the four of us with forks as all
others ate communally by hand), and honored us with
their generosity and hospitality. We asked for nothing,
and they gave their all to us and the community.
The connection of this experience to the creation,
growth, and influence of patient advocates and research
advocacy is clear to the author. Without fanfare, this vil-
lage demonstrates the power of collective action and
networking. And, it is an illustration of the author’s
belief that “Nothing is beyond the reach of a group of
dedicated, passionate people…anywhere or under any
circumstance on the planet.” Patient advocates—includ-
ing research advocates—can be one such dedicated, pas-
sionate force, changing the landscape of cancer in Africa
and working to defy the dire cancer incidence and death
projections in this region of the developing world.
Conclusions
The case for research advocacy in Africa is clear, and
the framework suggested is usable although not necessa-
rily the shape that research advocacy will take in coun-
tries and regions of Africa. In short, the framework
includes the creation of a partnership between advocates
and researchers, public and private support and invest-
ment, a research system that values patient input and
embeds research advocacy, a pipeline of individual citi-
zens willing and able to be (become) research advocates,
judicious borrowing from and tailored use of already
established models and concepts, and ongoing training
and preparation. But the devil, of course, will be in the
details and in the doing.
Advocates, through whatever subspecialty they engage,
can make a difference in cancer awareness and preven-
tion, incidence, care, and outcomes across Africa. In
fact, they have already begun to do so. The only quali-
fier is the requirement for action, that is, moving
beyond the rhetoric of urgency, recommendations,
grand statements to practical steps, assignments, rea-
soned collaborations, pilot projects, and implementation.
These are all feasible, all doable, all necessary.
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Additional material
Additional file 1: A tribute to patients and survivors This is a tribute
to cancer patients and survivors who give so much of themselves even
as they struggle through their own cancer journeys. In 2005, the author
and her daughter Nneka Scroggins planted a tree on the Masaai Mara in
Kenya in honor of cancer survivors everywhere.
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